EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
1 Cash-Heavy Stock to Target This Week and 2 We Ignore
Why Novavax (NVAX) Is Down 7.0% After Crushing Q4 Revenue And Earnings Forecasts - And What's Next - Simply Wall St News
Novavax, Inc. (NVAX) PT Increased as B. Riley Sees Governance-Driven Catalysts Ahead
FY2028 EPS Estimates for Novavax Cut by Zacks Research
Zacks Research Issues Negative Forecast for Novavax Earnings - Daily Political
Is It Time To Reconsider Novavax (NVAX) After Recent Share Price Weakness?
Spotting Winners: AbbVie (NYSE:ABBV) And Therapeutics Stocks In Q4
Head-To-Head Contrast: Synlogic (NASDAQ:SYBX) versus Novavax (NASDAQ:NVAX)
Assessing Novavax (NVAX) Valuation After Recent Share Price Volatility And Licensing Expectations
Chandrakant Lahariya | Flu-COVID Combo Vaccines: An Idea Whose Time Has Not Yet Arrived
Novavax, Inc. (NASDAQ:NVAX) Receives Consensus Recommendation of "Hold" from Analysts
Is It Time To Reassess Novavax (NVAX) After Recent Volatility And Partnership News
Is Novavax (NVAX) Being Pulled Between R&D Ambitions and Activist Demands for Discipline? - Simply Wall St News
Sanofi becomes market authorization holder for Nuvaxovid® in Canada, expanding COVID-19 vaccine choices for Canadians
Assessing Novavax (NVAX) Valuation After Renewed Focus On Covid And Malaria Vaccine Deals
Shah Capital intends to vote against Novavax's board nominees, executive compensation
Is Novavax (NVAX) A Potential Opportunity After Recent Share Price Weakness
Assessing Novavax (NVAX) Valuation After Recent Share Price Swings And Royalty Deal Outlook
Traders Buy Large Volume of Call Options on Novavax (NASDAQ:NVAX)
Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
Will Novavax's New R&D Chief Reframe Its Partnership-Led Strategy and Long-Term Story (NVAX)? - Simply Wall St News
Novavax (NASDAQ:NVAX) Shares Down 5.4% - Should You Sell? - Daily Political
Novavax (NASDAQ:NVAX) Shares Pass Above Two Hundred Day Moving Average - Should You Sell? - Stock Observer
2 Growth Stocks Set to Flourishand 1 We Question
New Novavax R&D Leader Raises Questions On Valuation Gap And Outlook
Novavax (NASDAQ:NVAX) Stock Price Passes Above 200 Day Moving Average - Here's Why
Shah Capital Management Purchases 2,747,000 Shares of Novavax, Inc. $NVAX - Daily Political
3 Companies Built Their Fortunes on COVID Vaccines, but Only 1 Has a Real Plan for What Comes Next
A Look Back at Biotechnology Stocks' Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
